Evidence map›Paper›PMID 35570144›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2022

[Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis].

Yi Chen, Xin Wang, Bing Sun, Maobin Meng, Enmin Wang, Zhiyong Yuan, Hongqing Zhuang, Society of Radiation Oncology, Chinese Medical Education Association

Open access · greenAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yi Chen *Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China.
Xin Wang *Department of Radiation Oncology, Fudan University Huashan Hospital, Shanghai 200000, China.
Bing Sun *Department of Radiation Oncology, The Fifth Medical Center of PLA General Hospital, Beijing 100000, China.
Maobin Meng *Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300000, China.
Enmin WangDepartment of Radiation Oncology, Fudan University Huashan Hospital, Shanghai 200000, China.
Zhiyong YuanDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300000, China.
Hongqing ZhuangDepartment of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China.
Society of Radiation Oncology, Chinese Medical Education Association
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular damage is followed by vascular endothelial growth factor (VEGF) expression at high levels, which is an important mechanism for cerebral radiation necrosis (CRN) development. Antiangiogenic agents (Bevacizumab) alleviates brain edema symptoms caused by CRN through inhibiting VEGF and acting on vascular tissue around the brain necrosis area. Many studies have confirmed that Bevacizumab effectively relieves symptoms caused by brain necrosis, improves patients' performance status and brain necrosis imaging. Considering that the efficacy of antiangiogenic therapy is mainly related to the duration of drug action, low-dose antiangiogenic agents can achieve favorable efficacy. Prevention is the best treatment. The occurrence of CRN is associated with tumor-related factors and treatment-related factors. By controlling these factors, CRN can be effectively prevented.
.

Indexed as

Lung NeoplasmsRadiation InjuriesAngiogenesis InhibitorsBevacizumabBrainConsensusHumansNecrosisVascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabVascular Endothelial Growth Factor AAntiangiogenic drugsBevacizumabExpert consensusRadioactive brain necrosis

Identifiers

PMID35570144
PMCPMC9127755
OpenAlexW4280617474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.